A recent study reveals that people who stop using new GLP-1 drugs like Mounjaro or Wegovy can put back on reduced body mass far faster than those who halt conventional diet and exercise programs.
Published data in a major health publication shows that while obese people frequently drop substantial amounts of their body weight while on the medication, the weight is regained at an estimated rate of 0.8 kg per month after stopping.
"Individuals buying these drugs must be cognizant of the risk of rapid weight regain when the medication is stopped," cautioned researcher Dr. Susan Jebb.
Such speed of regain means a return to pre-treatment weight in about 18 months.
Weighing Treatments
The study, which looked at dozens of trials involving over 9,000 of participants, contrasted the results of the injectable medications with other pills.
Researchers emphasize that individuals who lose weight through diet and exercise typically see a slower creep back—around 0.1 kg a month—once they finish.
The Reason for the Rapid Rebound
Nutrition scientists suggest the mechanism of the injections is key to understanding the accelerated weight return.
These medications copy a natural hormone called GLP-1, which helps regulate feelings of fullness.
"Sustained high doses of the hormone levels far above than normal might result in the body to produce less of its own natural hormone, and could lessen sensitivity to its actions," noted Dr. Adam Collins, a dietetics specialist.
"Discontinuation of this GLP-1 'fix' results in hunger is unsuppressed, making binge eating much more probable."
An Ongoing Issue?
Health authorities recommend the injections for people with obesity-related health risks, alongside recommended lifestyle changes.
Professionals contend that, given the significant potential of relapse, the treatment is often life-long.
This opinion is echoed by pharmaceutical companies, who note that the results "highlight the persistent nature of obesity," similar to managing conditions like diabetes.
Patient Experiences
Users who have discontinued the jabs explain a powerful resurgence of hunger.
"It was like something that goes on and I was suddenly ravenous," said a patient.
This challenge is exacerbated if users have not adopted permanent lifestyle or habit modifications during treatment.
Widespread Use
Survey data suggest that millions of adults in the UK have tried these injections in the last 12 months, with desire continuing to grow.
- Adoption is higher among females compared to men.
- The middle-aged demographic shows the greatest level of interest.
- A large proportion obtain the medications through private healthcare rather than the NHS.
Ultimately, clinicians stress that while these medications are powerful tools for weight loss, they are not a permanent solution and lasting health benefits likely depends on combined lifestyle management.
